ライフサイエンスコーパス: total gastrectomy

1 imilar to those of other patients undergoing total gastrectomy.

2 prompting a recommendation for prophylactic total gastrectomy.

3 d normalized costs following curative-intent total gastrectomy.

4 % 3-stage, 12% transhiatal, and 19% extended total gastrectomy.

5 cess approach for limited, subtotal and even total gastrectomy.

6 erwent proximal gastrectomy and 33 underwent total gastrectomy.

7 equired a distal gastrectomy and 71 required total gastrectomy.

8 %) of 270 patients proceeded to prophylactic total gastrectomy.

9 early all patients (98.4%) lost weight after total gastrectomy.

10 recommended to those who defer prophylactic total gastrectomy.

11 individuals with CDH1 variants who declined total gastrectomy.

12 while this association was not observed for total gastrectomy.

13 ticularly in those who declined prophylactic total gastrectomy.

14 subtotal (17.9% vs. 25.3%, P=0.005), but not total gastrectomy (31.5% vs. 36.1%, P=0.201).

15 Hispanics were more likely to require total gastrectomy (51%) compared with whites (38%), Afri

16 Among patients who had a prophylactic total gastrectomy after an endoscopy with biopsy samples

17 MATERIAL/Records of 104 consecutive total gastrectomies and distal esophagectomies were anal

18 A total gastrectomy and an esophagectomy for GEJ cancer sh

19 Both a total gastrectomy and an esophagectomy may be valid trea

20 gastrectomy and gastrojejunostomy (n = 5) or total gastrectomy and esophagojejunostomy (n = 4).

21 ness (three had nodal infiltration requiring total gastrectomy and one an adenocarcinoma) and iron-de

22 type, and pathologic data from risk-reducing total gastrectomy and surveillance endoscopy were examin

23 l gastrectomy, euro 6584 (US $6554) for open total gastrectomy, and euro 5893 (US $5866) for open dis

24 ue of creating a small-bowel reservoir after total gastrectomy are contended.

25 osuppressive regimes may be prescribed after total gastrectomy as long as their limitations are noted

26 dy was to describe postoperative outcomes of total gastrectomy at our institution for patients with h

27 ain, with the decision between antrectomy or total gastrectomy being empirical.

28 ere life-altering consequences attributed to total gastrectomy by some patients.

29 and 14% of 2-, 3-, transhiatal, and extended total gastrectomy cohorts, respectively (P=0.05).

30 ng esophagectomy, pancreatectomy, partial or total gastrectomy, colectomy, lung resection, and cystec

31 41 patients with CDH1 mutation who underwent total gastrectomy during 2005 to 2015.

32 to be euro 8124 (US $8087) for laparoscopic total gastrectomy, euro 7353 (US $7320) for laparoscopic

33 uded all patients undergoing curative-intent total gastrectomy for gastric adenocarcinoma between Jan

34 complications with hospital costs following total gastrectomy for gastric adenocarcinoma.

35 arameters, and overall quality of life after total gastrectomy for gastric malignancy.

36 sults in patients following esophagectomy or total gastrectomy for GEJ cancer.

37 sults in patients following esophagectomy or total gastrectomy for GEJ cancer.

38 otal, 120 patients underwent curative-intent total gastrectomy for stage I through III gastric adenoc

39 ients (42.5%) who underwent an uncomplicated total gastrectomy had a mean (SD) normalized cost of MP

40 CDH1 mutations are an indication for total gastrectomy in these patients.

41 experience of managing long-term sequelae of total gastrectomy in young patients.

42 terocutaneous fistulas, reconstruction after total gastrectomy, intestinal transit after ileocecal se

43 Prophylactic total gastrectomy is recommended for any pathogenic or l

44 ecent advances in reconstruction techniques, total gastrectomy is still accompanied by various compli

45 Prophylactic total gastrectomy is the definitive treatment.

46 Of the 41 patients undergoing total gastrectomy, median age was 47 years (range 20 to

47 ts either had subtotal resection (n = 29) or total gastrectomy (n = 97) for T1 gastric cancer.

48 Patients with GEJ cancer in whom a total gastrectomy or an esophagectomy was performed betw

49 tine radiological contrast swallow following total gastrectomy or distal esophagectomy cannot be reco

50 d plasma levels to be raised in humans after total gastrectomy or intestinal transplantation, but lar

51 , ASA 3/4 (OR = 0.68, 95% CI: 0.54-0.86) and total gastrectomy (OR = 0.56, 95% CI: 0.45-0.70), had a

52 .49, 95% CI, 0.30-0.80; P=0.005), but not in total gastrectomy (OR=1.15, 95% CI, 0.62-2.17; P=0.645).

53 16 variants]) who elected for risk-reducing total gastrectomy owing to their underlying CDH1 P/LP va

54 ical errors, and hazard zones enacted during total gastrectomy performed robotically and laparoscopic

55 ical errors, and hazard zones enacted during total gastrectomy performed robotically and laparoscopic

56 tions is generally to undertake prophylactic total gastrectomy (PTG).

57 Prophylactic total gastrectomy remains the recommended option for gas

58 ort- and long-term outcomes of risk-reducing total gastrectomy (RRTG) and its lesser-known impacts on

59 Total gastrectomy should be considered for all CDH1 muta

60 y reflected those identified in prophylactic total gastrectomy specimens than did targeted biopsies.

61 llance can inform the timing of prophylactic total gastrectomy through detection of microscopic signe

62 estomach (n = 51); esophagoduodenostomy plus total gastrectomy to produce reflux of duodenal juice al

63 old man of East Asian origin with a previous total gastrectomy was evaluated for living donor kidney

64 most patients have durable weight loss after total gastrectomy, weights stabilize at about 6 to 12 mo

65 ular breast carcinoma underwent prophylactic total gastrectomy which revealed multifocal intramucosal

66 Subsequently, they each underwent total gastrectomy with D-2 node dissection and Roux-en-Y

67 After total gastrectomy with Roux-en-Y-reconstruction, anastom

68 rm functional and nutritional outcomes after total gastrectomy, without greater perioperative morbidi